BlossomHill Therapeutics raises a $100M series B to work on precision medicine small molecules
- Mar 1, 2024
- 1 min read
Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations, and she previews three of BlossomHill's programs.









.png)
